Publications & Works

Publication Network
Articles 48
All (48)
SCI-E, SSCI, AHCI (40)
SCI-E, SSCI, AHCI, ESCI (44)
ESCI (4)
Scopus (44)
TRDizin (5)
Other Publications (1)

1. Digital multiplex ligation-dependent probe amplification identifies exon-level copy number variants in patients with suspected hereditary cancer and negative next-generation sequencing results

DURMAZ ÖZDİNÇ C. D., Bulut N. S., ERKAN KOLAÇ D. D., KERTMEN N., AKÇİN Ö. Ç., DİZDAR Ö., et al.
Molecular Biology Reports , vol.53, no.1, 2026 (SCI-Expanded, Scopus)

2. Serum Vitamin D Levels as a Prognostic Biomarker in Patients Receiving Immune Checkpoint Inhibitors

Şahi̇n T. K., BAŞ O., KAVGACI G., Güdük N., ŞİRVAN F., AKIN S., et al.
Journal of Oncological Science , vol.12, no.1, pp.1-8, 2026 (Scopus, TRDizin) Creative Commons License

3. Prognostic significance of ductal carcinoma in situ coexisting with invasive ductal carcinoma: Biological behavior, immune response and survival outcomes

Fedai N. K., Koc I., KAVGACI G., ÜNER M., ÜNER A., AKSOY S., et al.
Molecular and Clinical Oncology , vol.24, no.1, 2026 (ESCI, Scopus)

4. Advancing Intracranial Tumor Treatment Through Gyroscopic Radiosurgery-Based Lattice Therapy: Evidence From a Case Series Study.

Yilmaz M. T., Yedekci F. Y., Mohammadipour S., Kivanc H., Cengiz M., Cifci G., et al.
Cureus , vol.17, no.6, 2025 (ESCI)

5. Sequential immunotherapy and bevacizumab treatments in glioblastoma multiforme: A case series and review of the literature

KERTMEN N., KAVGACI G., Koc I., PARLAK SAĞOL Ş., IŞIKAY A. İ., YAZICI G.
ONCOLOGY LETTERS , vol.29, no.3, 2025 (SCI-Expanded, Scopus)

6. Evaluating Immunotherapy Responses in Neuro-Oncology for Glioblastoma and Brain Metastases: A Brief Review Featuring Three Cases

KERTMEN N., KAVGACI G., AKIN S., ÇOBAN ÇİFÇİ G., IŞIKAY A. İ., YAZICI G.
CANCER CONTROL , vol.32, 2025 (SCI-Expanded, Scopus)

7. Hypo-fractionated Stereotactic Re-Irradiation Outcomes For Recurrent Glioblastoma

Yilmaz M. T., KAHVECİOĞLU A., Mohammadipur S., Zorlu F., Oge K., KERTMEN N., et al.
RADIOTHERAPY AND ONCOLOGY , 2024 (SCI-Expanded, Scopus)

8. Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center

Yilmaz M. T., KAHVECİOĞLU A., YAZICI G., Mohammadipour S., KERTMEN N., Cifci G. C., et al.
Journal of Neuro-Oncology , vol.167, no.2, pp.295-303, 2024 (SCI-Expanded, Scopus)

9. Acute heart failure following pazopanib treatment: a literature review featuring two case reports

KERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.
Anti-Cancer Drugs , vol.35, no.3, pp.302-304, 2024 (SCI-Expanded, Scopus)

10. Comparison of different target volume delineation strategies based on recurrence patterns in adjuvant radiotherapy for glioblastoma.

Yilmaz M. T., Kahvecioglu A., Yedekci F. Y., Yigit E., Ciftci G. C., Kertmen N., et al.
Neuro-oncology practice , vol.11, no.3, pp.275-283, 2024 (ESCI, Scopus)

11. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia

AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.
Current Oncology , vol.30, no.11, pp.9689-9700, 2023 (SCI-Expanded, Scopus) Creative Commons License

12. Low-grade glial tumors: The experience of an oncology hospital in Türkiye

CEYLAN S., KERTMEN N., YAZICI G., KARS A.
Acta Medica , vol.54, no.2, pp.151-156, 2023 (TRDizin) Creative Commons License

13. SMART syndrome: a case report

Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., et al.
ACTA NEUROLOGICA BELGICA , vol.123, no.3, pp.1137-1140, 2023 (SCI-Expanded, Scopus) Creative Commons License Sustainable Development

14. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer

KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., et al.
Biomarkers in Medicine , vol.17, no.7, pp.379-389, 2023 (SCI-Expanded, Scopus)

15. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment

Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.
Expert Review of Anticancer Therapy , vol.23, no.10, pp.1049-1059, 2023 (SCI-Expanded, Scopus)

16. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards

GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.8, pp.1807-1811, 2022 (SCI-Expanded, Scopus) Sustainable Development

17. Cerebellar Hypermetabolism: An Alternative Marker for Diagnosis of Paraneoplastic Cerebellar Degeneration.

Arslan D., Ardıc F. S., Gultekin-Zaim O. B., Tuncel M., Kertmen N., Gocmen R., et al.
Neurologia (Barcelona, Spain) , 2022 (Peer-Reviewed Journal)

18. THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapy

Aktepe O. H., Gundogdu F., Kosemehmetoglu K., Yeter H. H., Aksoy S., Guven D. C., et al.
IRISH JOURNAL OF MEDICAL SCIENCE , vol.191, no.4, pp.1561-1567, 2022 (SCI-Expanded, Scopus)

19. Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer

YEKEDÜZ E., DİZDAR Ö., KERTMEN N., AKSOY S.
JOURNAL OF CLINICAL MEDICINE , vol.11, no.9, 2022 (SCI-Expanded, Scopus) Creative Commons License

20. HER2-low breast cancer could be associated with an increased risk of brain metastasis

GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.27, no.2, pp.332-339, 2022 (SCI-Expanded, Scopus) Sustainable Development

21. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.
FUTURE ONCOLOGY , vol.18, pp.323-331, 2022 (SCI-Expanded, Scopus) Sustainable Development

22. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES , vol.52, no.5, pp.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

23. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme

GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.
FUTURE ONCOLOGY , vol.17, pp.4405-4413, 2021 (SCI-Expanded, Scopus) Sustainable Development

24. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus) Creative Commons License Sustainable Development

25. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.
SUPPORTIVE CARE IN CANCER , vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded, Scopus) Sustainable Development

26. Sarcopenia and anthracycline cardiotoxicity in patients with cancer

BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus) Sustainable Development

27. Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?

Sari S. Y., AKTAŞ B. Y., KERTMEN N., ELMALI A., Kilickap S., Oguz K. K., et al.
CUREUS , vol.13, no.6, 2021 (ESCI) Creative Commons License

28. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.
CANCER RESEARCH , vol.81, no.4, 2021 (SCI-Expanded, Scopus) Sustainable Development

29. COVID-19 pandemic: changes in cancer admissions.

Guven D. C., Aktas B. Y., Aksun M. S., Ucgul E., Sahin T. K., Yildirim H. C., et al.
BMJ supportive & palliative care , 2020 (SCI-Expanded, Scopus) Creative Commons License Sustainable Development

30. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma

BAŞ O., Ozbek A., Guven D., Aktepe O., KILIÇ L., KERTMEN N., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.5, pp.1230-1233, 2020 (SCI-Expanded, Scopus)

31. Depression and anxiety in oncology nurses.

Keskin O., Oktay E., Turan M., Kertmen N., Tanriverdi O., Imamoglu G. I., et al.
JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018 (SCI-Expanded, Scopus)

32. Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancers

Karakas Y., KERTMEN N., LAÇİN Ş., Aslan A., DEMİR M., ATEŞ Ö., et al.
JOURNAL OF BUON , vol.22, no.3, pp.623-627, 2017 (SCI-Expanded, Scopus) Sustainable Development

33. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience

Sarici F., BABACAN T., Buyukhatipoglu H., Balakan O., SEVER A. R., KERTMEN N., et al.
JOURNAL OF BUON , vol.21, no.4, pp.826-831, 2016 (SCI-Expanded, Scopus)

34. Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors

ATEŞ Ö., SOYLU C., BABACAN T., Sarici F., KERTMEN N., Allen D., et al.
SPRINGERPLUS , vol.5, 2016 (SCI-Expanded, Scopus) Sustainable Development

35. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer

ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., et al.
JOURNAL OF BUON , vol.21, no.2, pp.375-381, 2016 (SCI-Expanded, Scopus) Sustainable Development

36. Anthracyclin - Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75

Sarici F., KERTMEN N., Aslan A. C., Tasdemir V., BABACAN T., KILIÇKAP S., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.2, pp.89-95, 2016 (SCI-Expanded, Scopus, TRDizin) Creative Commons License Sustainable Development

37. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer

BABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., et al.
TUMORI J , vol.101, no.4, pp.418-423, 2015 (SCI-Expanded, Scopus) Sustainable Development

38. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality

Solak M., Turkoz F. P., Keskin O., AKSOY S., BABACAN T., Sarici F., et al.
JOURNAL OF BUON , vol.20, no.3, pp.737-745, 2015 (SCI-Expanded, Scopus) Sustainable Development

39. Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis

BABACAN T., Buyukhatipoglu H., Balakan O., KERTMEN N., Suner A., Sarici F., et al.
JOURNAL OF BUON , vol.20, no.2, pp.479-486, 2015 (SCI-Expanded, Scopus) Sustainable Development

40. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+breast cancer patients

BABACAN T., Balakan O., Kuzan T. Y., Sarici F., Koca E., KERTMEN N., et al.
JOURNAL OF BUON , vol.20, no.1, pp.50-56, 2015 (SCI-Expanded, Scopus) Sustainable Development

41. which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in rats

KERTMEN N.
Hacettepe Journal of Biology and Chemistry , vol.15, pp.1056-1058, 2015 (Scopus, TRDizin) Creative Commons License

42. Comparison of three different induction regimens for nasopharyngeal cancer

KERTMEN N., AKSOY S., CENGİZ M., YAZICI G., KESKİN O., Babacan T., et al.
Asian Pacific Journal of Cancer Prevention , vol.16, no.1, pp.59-63, 2015 (SCI-Expanded, Scopus) Creative Commons License Sustainable Development

43. Molecular subtypes in patients with inflammatory breast cancer; A single center experience

KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., et al.
JOURNAL OF BUON , vol.20, no.1, pp.35-39, 2015 (SCI-Expanded, Scopus) Sustainable Development

44. A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literature

Keskin O. D., KERTMEN N., Karakas Y., BABACAN T., ARIK Z., Altundag K., et al.
JOURNAL OF BUON , vol.20, no.1, pp.348, 2015 (SCI-Expanded, Scopus)

45. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer

Buyukhatipoglu H., BABACAN T., KERTMEN N., Balakan O., Suner A., ATEŞ Ö., et al.
JOURNAL OF BUON , vol.20, no.1, pp.22-27, 2015 (SCI-Expanded, Scopus)

46. Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab

ATEŞ Ö., Sunar V., BABACAN T., AKIN S., KERTMEN N., Altundag K.
JOURNAL OF BUON , vol.20, no.1, pp.349, 2015 (SCI-Expanded, Scopus)

47. Which sequence best protects the heart against trastuzumab and anthracycline toxicity An electron microscopy study in rats

KERTMEN N., AKSOY S., ÜNER A., ÖZGÜR Ö., keskin o., babacan t., et al.
Anticancer Research , 2015 (SCI-Expanded, Scopus)

48. Association between common risk factors and molecular subtypes in breast cancer patients

Turkoz F. P., Solak M., Petekkaya I., Keskin O., KERTMEN N., Sarici F., et al.
BREAST , vol.22, no.3, pp.344-350, 2013 (SCI-Expanded, Scopus)
Papers Presented at Peer-Reviewed Scientific Conferences 20

1. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital

Guven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, (Summary Text)

2. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience

AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, (Summary Text) Sustainable Development

3. Effectiveness and safety of ferric carboxymaltose to treat iron deficiency anemia in cancer patients.

Aktas B. Y., Kayku V. E., Aslan A., Kertmen N., Dizdar Ö., Yalcin S., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text) Sustainable Development

4. Depression and anxiety in oncology nurses.

KESKİN Ö., OKTAY E., TURAN M., KERTMEN N., TANRIVERDİ Ö., İMAMOĞLU İNANÇ G., et al.
2018 ASCO Annual Meeting, United States Of America, 5 - 08 June 2018, pp.18552, (Full Text)

5. Onkoloji Hemşirelerinde depresyon ve anksiyete

KESKİN Ö., OKTAY E., TURAN M., KERTMEN N., TANRIVERDİ Ö., İMAMOĞLU G. İ., et al.
22.ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017, (Summary Text)

6. TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ

KERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., et al.
22. UKK, Turkey, 19 - 23 April 2017, (Summary Text)

7. Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma

ATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., et al.
2016 ASCO Annual Meeting, 29 May - 03 June 2016, (Full Text)

8. Intravenous ferric carboxymaltose treatment in cancer patients

ASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.
2016 ASCO Annual Meeting, 29 May - 03 June 2016, (Full Text) Sustainable Development

9. Kadri Altundag Taner Babacan Orhan Efe Ahmet S Hasırcı Fatih Demirci Hakan Buyukhatıpoglu Ozan Balakan Furkan Saim Sarıcı Neyran Kertmen Ece Esin Serkan Akin Ozturk Ates Sercan Aksoy Ali R Sever

ALTUNDAĞ M. K., Babacan T., EFE O., HASIRCI A. S., DEMİRCİ F., BUYUKHATİPOGLU H., et al.
2015 ASCO Annual Meeting, 29 May - 02 June 2015, (Full Text)

10. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer

Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al.
ASCO Annual Meeting, 29 May - 02 June 2015, (Full Text) Sustainable Development

11. Neuroendocrine breast cancer A single center experience

TAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., et al.
2015 ASCO Annual Meeting, 29 May - 02 June 2015, (Full Text) Sustainable Development

12. Tumor locations significantly affect disease free survival and overall survival

BUYUKHATİPOGLU H., Babacan T., KERTMEN N., Ateş Ö., AKTAŞ G., ŞENDUR M. A. N., et al.
2015 ASCO Annual Meeting, 29 May - 02 June 2015, (Full Text)

13. Signet ring cell carcinoma of breast: Single center experience.

AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)

14. Correlation of educational status and clinicopathological characteristics of breast cancer: A single center experience.

Diker O., Babacan T., Buyukhatipoglu H., Kertmen N., Balakan O., Sever A. R., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text) Sustainable Development

15. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.

Altundag K., Babacan T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text) Sustainable Development

16. Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.

Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text) Sustainable Development

17. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats

Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text)

18. Clinicopathologic characteristics of pure papillary breast carcinoma

Turkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text)

19. Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer.

Unlu O., Aygun S., Petekkaya H., Gecmez G., Roach E. C., Babacan T., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text) Sustainable Development

20. The impact of adjuvant delayed radiotheraphy (RT) on survival in patients with resected periampullary adenocarcinomas.

Yalcin S., Kertmen N., Yuce D., Yildiz F., Hamaloglu E.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text)
Metrics

Publication

68

Publication (WoS)

56

Publication (Scopus)

47

Citation (WoS)

297

H-Index (WoS)

8

Citation (Scopus)

247

H-Index (Scopus)

10

Project

4

Thesis Advisory

5

Open Access

17
UN Sustainable Development Goals
SDG 3: GOAL 3: GOOD HEALTH AND WELL-BEING